Brodalumab 210mg SC ( DrugBank: Brodalumab )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 37 | 膿疱性乾癬（汎発型） | 1 |
37. 膿疱性乾癬（汎発型）
臨床試験数 : 74 / 薬物数 : 53 - (DrugBank : 20) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 101
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04183881 (ClinicalTrials.gov) | July 4, 2016 | 29/11/2019 | A Phase 4 Clinical Study of Brodalumab | An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma | Psoriasis Vulgaris;Psoriatic Arthritis;Pustular; Psoriasis, Palmaris Et Plantaris;Psoriatic Erythroderma | Drug: Brodalumab 210mg SC | Kyowa Kirin Co., Ltd. | NULL | Completed | 18 Years | N/A | All | 138 | Phase 4 | Japan |